Gloria David, Ph.D., M.H.Sc

Principal Research Scientist

Gloria David

Gloria David, Ph.D., M.H.Sc

Principal Research Scientist

Dr. David holds a PhD in Pharmacology and Molecular Sciences from Johns Hopkins University School of Medicine, a Master of Health Sciences in Clinical Research from Duke University School of Medicine, and a BS in Biochemistry from the Pennsylvania State University.

Dr. David serves as Rho PI for the Medical Countermeasures Clinical Studies Network (MCM-CSN) contract funded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), Biomedical and Advanced Research Development Authority (BARDA). Under this contract, Rho provides clinical services to facilitate medical countermeasure product development toward licensure. Trials evaluate chemical, biological, radiological, nuclear, pandemic influenza, and emerging infectious diseases countermeasures. Dr. David has served as PI for 3 studies funded by BARDA: a Phase 2 study to investigate the efficacy of H7 influenza vaccine with adjuvants as a safeguard to the public against pandemic influenza, a Phase 2 study to investigate the safety and immunogenicity of anthrax vaccine in individuals over 65, and a Phase 1 study to assess the bioavailability and pharmacokinetics of atropine as a countermeasure for nerve agent poisoning.

Dr. David also currently serves as a Lead Scientist for the Asthma and Allergic Diseases Group for the NIAID Division of Allergy, Immunology, and Transplantation: Statistical and Clinical Coordinating Center (2015-2022). She is responsible for the scientific and technical oversight of the performance of the coordinating center’s work, including clinical operations, data management, and statistical, technical, regulatory, and administrative support. She works directly with the NIAID Project Office and clinical investigators to define project needs and is responsible for building cross-functional teams at Rho to meet those needs and for coordinating all activities to ensure the successful completion of all projects. She also provides oversight for subcontractor activities (e.g., drug distribution, safety labs, sample analysis, and repository sample storage).
Dr. David also has served as co-PI of the Statistical and Clinical Coordinating Center (SACCC) for the NIAID-funded Inner-City Asthma Consortium (ICAC; 2004-2015) and as PI of the NIAID-funded Atopic Dermatitis Vaccinia Network (ADVN; 2008-2011) and the Atopic Dermatitis Research Network (ADRN; 2010-2015) Coordinating Centers.

Dr. David has provided scientific and technical leadership for 6 vaccine studies funded by the NIAID. She served as PI on 2 studies in patients with atopic dermatitis examining the safety and immunogenicity of an intradermal influenza vaccine. She also served as co-PI on a study assessing the safety and immunogenicity of the 2009 H1N1 vaccine in adults and children with severe asthma. She has provided leadership for a yellow fever vaccine study and a varicella vaccine study in patients with atopic dermatitis and for a keyhole limpet hemocyanin adjuvant study.